STOCK TITAN

Vor Biopharma (VOR) director receives 42,658 stock options at $20.10 strike

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Vor Biopharma director David Zaccardelli received a new stock option grant. The award covers 42,658 options to buy Vor Biopharma common stock at an exercise price of $20.10 per share and expires on July 6, 2036. These options will vest in 36 equal monthly installments beginning on August 7, 2026, contingent on his continued service with the company.

Positive

  • None.

Negative

  • None.
Insider ZACCARDELLI DAVID
Role null
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 42,658 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 42,658 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Options granted 42,658 options Stock Option (Right to Buy) grant to director
Exercise price $20.10 per share Strike price for Vor Biopharma common stock
Expiration date July 6, 2036 Option term end date
Underlying shares 42,658 shares Common stock underlying the options
Vesting period 36 monthly installments Beginning August 7, 2026, subject to continued service
Post-grant derivative holdings 42,658 options Total derivative securities following the transaction
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
exercise price financial
"conversion_or_exercise_price: 20.1000"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: 2036-07-06T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
vesting financial
"The shares shall vest and become exercisable in a series of 36 successive equal monthly installments"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
underlying security financial
"underlying_security_title: Common Stock"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What did Vor Biopharma (VOR) disclose about David Zaccardelli in this Form 4?

Vor Biopharma reported that director David Zaccardelli received a stock option grant for 42,658 shares. The options give him the right to buy common stock at $20.10 per share, subject to a multi-year vesting schedule tied to continued service.

How many Vor Biopharma (VOR) stock options were granted to David Zaccardelli?

David Zaccardelli was granted stock options covering 42,658 shares of Vor Biopharma common stock. These options represent a new compensation award and are scheduled to vest over time, rather than being immediately exercisable on the grant date.

What is the exercise price of David Zaccardelli’s Vor Biopharma (VOR) stock options?

The exercise price of David Zaccardelli’s stock options is $20.10 per share. This is the fixed price he must pay to purchase Vor Biopharma common shares when vested options are eventually exercised in the future.

When do David Zaccardelli’s Vor Biopharma (VOR) stock options start vesting?

The options begin vesting on August 7, 2026. Vesting then continues in 36 equal monthly installments, meaning the award becomes exercisable gradually over three years, as long as he continues serving the company on each vesting date.

When do David Zaccardelli’s Vor Biopharma (VOR) stock options expire?

The stock options granted to David Zaccardelli expire on July 6, 2036. After this expiration date, any unexercised options will lapse, so they must be both vested and exercised before that deadline to convert into common shares.

Are David Zaccardelli’s Vor Biopharma (VOR) options immediately exercisable?

No, the options are not immediately exercisable. They vest and become exercisable in 36 equal monthly installments starting August 7, 2026, and each installment requires David Zaccardelli to remain in service on the respective vesting date.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
ZACCARDELLI DAVID

(Last)(First)(Middle)
500 BOYLSTON STREET, SUITE 1350

(Street)
BOSTON MASSACHUSETTS 02116

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Vor Biopharma Inc. [ VOR ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/07/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$20.107/07/2026A42,658 (1)07/06/2036Common Stock42,658$042,658D
Explanation of Responses:
1. The shares shall vest and become exercisable in a series of 36 successive equal monthly installments beginning on August 7, 2026, in each case subject to the Reporting Person's continued service as of each such date.
/s/ Adi Osovsky, Attorney-in-Fact07/09/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)